GILEAD SCIENCES, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Gilead Sciences (GILD) reported Q2 revenue of $7.8B, up 10% YoY, with HIV sales at $5.7B, up 12%. Recent FDA approvals include Bixlenvo for HIV and label expansion for Trodelvy in cancer. The company expects Hepcludex to boost liver disease sales. GILD offers a 2.2% dividend yield, higher than the S&P 500 average.
Gilead Sciences (GILD) reported its HIV prevention (PrEP) sales exceeded $1 billion in Q2 2026, doubling from the previous year. Products Descovy and Yeztugo drove this growth, with Descovy generating $801 million in prevention sales. The company raised its HIV sales growth forecast to 9-10% for fiscal 2026 and announced an agreement to expand access to Yeztugo in Latin America and the Caribbean. GILD stock has risen 36.1% over the past year, trading at 6.4 times sales.
Gilead Sciences' Chief Commercial & Corporate Affairs Officer Johanna Mercier sold 3,000 shares on 2026-10-15, reducing her stake to 113,684 shares. The sale occurred at $156.22 per share, with the company's market cap at $193.67 billion. Mercier has sold 136,000 shares over the past year with no purchases, continuing a trend of insider selling at Gilead.
Over the past 7 days, AlphAI's AI scored 14 news stories mentioning GILD (GILEAD SCIENCES, INC.). Coverage has skewed bullish: 10 bullish, 3 neutral, and 1 bearish.
Recent GILD coverage spans regulation, financial news and earnings.
In the last 30 days, GILD insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($3.2M). The most active reporter was O'Day Daniel Patrick, Chairman & CEO, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The approvals expand Gilead's product portfolio and open new revenue streams, likely supporting share price appreciation.
Strong prevention sales signal accelerating growth beyond HIV treatment, likely supporting the stock.
The sale adds to ongoing insider divestiture, suggesting potential downside pressure.
Adds a lucrative first‑line indication, supporting revenue growth.
Gilead likely to ride the sector‑wide inflow.
AlphAI scores every news story that mentions GILD with an AI model for sentiment and relevance, and aggregates insider trades from GILEAD SCIENCES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Gilead Sciences (GILD) reported Q2 revenue of $7.8B, up 10% YoY, with HIV sales at $5.7B, up 12%. Recent FDA approvals include Bixlenvo for HIV and label expansion for Trodelvy in cancer. The company expects Hepcludex to boost liver disease sales. GILD offers a 2.2% dividend yield, higher than the S&P 500 average.
3 min readGilead Sciences (GILD) reported its HIV prevention (PrEP) sales exceeded $1 billion in Q2 2026, doubling from the previous year. Products Descovy and Yeztugo drove this growth, with Descovy generating $801 million in prevention sales. The company raised its HIV sales growth forecast to 9-10% for fiscal 2026 and announced an agreement to expand access to Yeztugo in Latin America and the Caribbean. GILD stock has risen 36.1% over the past year, trading at 6.4 times sales.
2 min readGilead Sciences' Chief Commercial & Corporate Affairs Officer Johanna Mercier sold 3,000 shares on 2026-10-15, reducing her stake to 113,684 shares. The sale occurred at $156.22 per share, with the company's market cap at $193.67 billion. Mercier has sold 136,000 shares over the past year with no purchases, continuing a trend of insider selling at Gilead.
2 min readThe FDA approved several breast cancer treatments in 2026, including Daiichi Sankyo's fam-trastuzumab deruxtecan for early-stage HER2-positive breast cancer, datopotamab deruxtecan for triple-negative breast cancer, Gilead Sciences' sacituzumab govitecan for first-line TNBC, Pfizer's palbociclib for maintenance therapy, and AstraZeneca's camizestrant for HR-positive, HER2-negative advanced breast cancer.
5 min readAI stocks faced volatility, prompting capital rotation into pharmaceuticals. Eli Lilly (LLY) and AbbVie (ABBV) neared record highs, with LLY at $1,251.61 and ABBV at $283.40. Healthcare ETF XLV hit $177.19. LLY's gains were driven by its GLP-1 dominance and M&A activity, while ABBV's rally followed positive Skyrizi data. Other large-cap pharma stocks also rose, but biotech ETF XBI declined 2.8% over a month.
3 min readPerrigo (PRGO) gained 3.77% on a $10M lawsuit settlement. Gilead (GILD) rose 3.8% after an analyst raised its price target. Kroger (KR) increased 3.87% despite 3K job cuts. Bristol-Myers (BMY) climbed 4.61% on positive drug trial results.
1 min readBofA Securities raised its price target on Gilead Sciences (GILD) to $164 from $162, maintaining a Buy rating. The stock is trading at $151.17. BofA projects strong Q3 sales for several Gilead drugs and expects growth in oncology and immunology pipelines. Gilead's Q2 2026 earnings beat expectations, with revenue of $7.8 billion. The company also announced collaborations with Assembly Biosciences and MacroGenics.
2 min readGilead Sciences (GILD) stock rose 24% YTD, outperforming the S&P 500. Its forward P/E is 15.5, based on normalized earnings. Q2 2026 revenue grew 10% to $7.8B, with HIV sales up 12%. Gilead gained FDA approvals for Yeztugo and Hepcludex, adding growth drivers.
2 min readA CEA report indicates 72,000 U.S. manufacturing jobs added in 2026, driven by Trump's re-shoring policies and the One Big Beautiful Bill Act (OBBB). Companies like Jergens and Ketchie expanded due to OBBB provisions, with manufacturing wages up 7.9%. Investments include Micron's $250B in chip plants and Apple's $600B in semiconductors.
5 min readU.S. stocks rose on Friday, led by tech, with all three major indexes gaining weekly. The Dow added 423 points, S&P 500 up 46, Nasdaq up 173. OpenAI's revenue miss caused a tech selloff, but rebound followed. Nvidia, Micron, and others recovered. Trump announced a Russia diesel deal, pushing indexes higher. Treasury yields remain elevated. Apple shares fell 1.1% on production cuts. Moderna and Novavax surged on vaccine news. Telecoms dropped on SpaceX's spectrum acquisition.
3 min read
